NEWSROOM

Resource Type: Blog

Discover how RAM Discover uses AI to investigate asset trends, uncover failure patterns, and support faster life sciences decisions.
A capability-level look at what moves from RAM R3 to R4 — work records, audit trails, workflows, analytics, and integration — plus how to model your own numbers.
Meet EU Annex 11 and GMP expectations with a validated computerized system. RAM delivers audit trails, IQ/OQ/PQ, and inspection-ready documentation.
EU GMP Annex 11 requires computerized systems in regulated environments to be validated, controlled, and documented across their lifecycle. See how a validated platform carries the evidentiary weight — and what the coming Annex 11 revision means for your EU operations.
FDA’s April 2, 2026 Warning Letter to Purolea Cosmetics Lab appears to be one of the first publicly visible FDA drug CGMP enforcement actions to cite inappropriate AI use in pharmaceutical manufacturing. The lesson: AI changes the mode of error, not the locus of responsibility.
FDA and EMA’s January 2026 joint AI principles establish guardrails for AI use across manufacturing and the medicines lifecycle. For GxP operations teams, this means documented context of use, risk-tiered validation, ALCOA+ data governance, and lifecycle monitoring planned before drift occurs.
FDA inspection readiness starts long before an auditor arrives. Explore 9 pillars GMP manufacturers can use to strengthen documentation, asset control, training, and inspection response.
Disconnected EAM and QMS systems create real gaps in GMP operations—slowing investigations, increasing manual work, and introducing compliance risk. Here’s why integrating maintenance and quality systems is becoming essential—and how it creates a single, connected foundation for modern life sciences manufacturing.
Every SaaS release triggers the same validation question: re-test everything or document the update? This CSA playbook shows how to assess vendor releases, select the right regression tier, and maintain a defensible validated state.
Choosing a CMMS or EAM implementation model in a GMP environment is not just a project management decision — it determines where validation effort, operational strain, and compliance risk land across your go-live. In this guide, you’ll compare big-bang, phased, compliance-first, and patchwork approaches to identify the implementation model that best fits your data readiness, QA bandwidth, and audit pressure.

Subscribe for Updates

"*" indicates required fields

You can update your preferences or unsubscribe at any time. By submitting, you agree that Blue Mountain may store and process your information to provide the requested content. Read our Privacy Policy.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form